Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.93
−$0.05 · -1.00%
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Regular session
$4.93
−$0.05 · -1.00%
Regular session · ET · Market data may be delayed.
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Day range
Current $4.93
52-week range
Current $4.93
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
40
Bearish
Risk
62
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Day range
Current $4.93
52-week range
Current $4.93
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 59.43M USD | 56.94M USD | 50.16M USD | 53.87M USD | 49.11M USD |
| Cost of goods sold | 30.9M USD | 28.39M USD | 29.4M USD | 29.53M USD | 23.63M USD |
| Gross profit | 28.53M USD | 28.56M USD | 20.75M USD | 24.34M USD | 25.48M USD |
| Research and development | 9.08M USD | 6.83M USD | 9.54M USD | 11.55M USD | 9.37M USD |
| Selling, general, and administrative | 20.47M USD | 16.88M USD | 18.13M USD | 17.24M USD | 15.5M USD |
| Operating expenses | 29.67M USD | 23.71M USD | 27.68M USD | 28.79M USD | 24.87M USD |
| Depreciation and amortization | 1.38M USD | 1.64M USD | 1.87M USD | 2.25M USD | 1.63M USD |
| Operating income | −1.14M USD | 4.85M USD | −6.92M USD | −4.45M USD | 607K USD |
| Net income | −1.18M USD | 4.7M USD | −7.28M USD | −5.34M USD | 548K USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.00
143.41% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 12, 2015 | 1:12 | — | — |
Effective Aug 12, 2015
1:12
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
